))
S3 Episode 4: PsA Pipeline Evaluation: Progress and Unmet Needs
Manage episode 364203819 series 3291808
Medscape Podcasts에서 제공하는 콘텐츠입니다. 에피소드, 그래픽, 팟캐스트 설명을 포함한 모든 팟캐스트 콘텐츠는 Medscape Podcasts 또는 해당 팟캐스트 플랫폼 파트너가 직접 업로드하고 제공합니다. 누군가가 귀하의 허락 없이 귀하의 저작물을 사용하고 있다고 생각되는 경우 여기에 설명된 절차를 따르실 수 있습니다 https://ko.player.fm/legal.
Drs Stanley Cohen and Philip Mease review the 2022 ACR meeting topics, including new treatments, trial data, and what they think are the most pressing unmet needs in the field.
Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/984271). The topics and discussions are planned, produced, and reviewed independently of the advertisers. This podcast is intended only for US healthcare professionals.
Resources
Etanercept in the Treatment of Psoriatic Arthritis and Psoriasis: A Randomised Trial https://pubmed.ncbi.nlm.nih.gov/10972371/
Group for Research and Assessment of Psoriasis and Psoriatic Arthritis https://www.grappanetwork.org/
American College of Rheumatology (ACR) Convergence https://www.rheumatology.org/Annual-Meeting
Bimekizumab Treatment in Biologic DMARD-Naïve Patients With Active Psoriatic Arthritis: 52-Week Efficacy and Safety Results From a Phase 3, Randomized, Placebo-Controlled, Active Reference Study https://acrabstracts.org/abstract/bimekizumab-treatment-in-biologic-dmard-naive-patients-with-active-psoriatic-arthritis-52-week-efficacy-and-safety-results-from-a-phase-3-randomized-placebo-controlled-active-reference-study/
Bimekizumab Treatment in Patients With Active Psoriatic Arthritis and Inadequate Response to Tumor Necrosis Factor Inhibitors: 16-Week Efficacy and Safety From a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study https://acrabstracts.org/abstract/bimekizumab-treatment-in-patients-with-active-psoriatic-arthritis-and-inadequate-response-to-tumor-necrosis-factor-inhibitors-16-week-efficacy-and-safety-from-a-phase-3-randomized-double-blind-pla/
Bimekizumab Improvements in Efficacy on Disease Activity Assessed via Composite Endpoints in Biologic DMARD-Naïve and TNFi-IR Patients With Active PsA: Pooled 16-Week Results From Phase 3 Randomized, Placebo-Controlled Studies https://acrabstracts.org/abstract/bimekizumab-improvements-in-efficacy-on-disease-activity-assessed-via-composite-endpoints-in-biologic-dmard-naive-and-tnfi-ir-patients-with-active-psa-pooled-16-week-results-from-phase-3-randomized/
Bimekizumab Versus Adalimumab in Plaque Psoriasis https://pubmed.ncbi.nlm.nih.gov/33891379/
A Head-to-Head Comparison of the Efficacy and Safety of Ixekizumab and Adalimumab in Biological-Naïve Patients With Active Psoriatic Arthritis: 24-Week Results of a Randomised, Open-Label, Blinded-Assessor Trial https://pubmed.ncbi.nlm.nih.gov/31563894/
GRAPPA Treatment Recommendations: 2021 Update https://pubmed.ncbi.nlm.nih.gov/35293339/
Deucravacitinib Prescribing Information https://packageinserts.bms.com/pi/pi_sotyktu.pdf
Safety and Efficacy of Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 Inhibitor, in Patients With Psoriatic Arthritis: 52-Week Results From a Randomized Phase 2 Trial https://acrabstracts.org/abstract/safety-and-efficacy-of-deucravacitinib-an-oral-selective-tyrosine-kinase-2-inhibitor-in-patients-with-psoriatic-arthritis-52-week-results-from-a-randomized-phase-2-trial/
Deucravacitinib Reduces Interferons, B Cell Pathways, and Serological Biomarkers of Systemic Lupus Disease Activity: Pharmacodynamic Analysis From the Phase 2 PAISLEY Study https://acrabstracts.org/abstract/deucravacitinib-reduces-interferons-b-cell-pathways-and-serological-biomarkers-of-systemic-lupus-disease-activity-pharmacodynamic-analysis-from-the-phase-2-paisley-study/
Nanobody: A Promising Toolkit for Molecular Imaging and Disease Therapy https://pubmed.ncbi.nlm.nih.gov/33464410/
18 에피소드
공유
